Related Experiment Videos
Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice
1Preventive Cardiology, Sterling Rock Falls Clinic, Ltd, Sterling, IL 61081, USA. peter.toth@srfc.com
Abstract:
Achieving adequate control of cardiovascular risk in type 2 diabetes mellitus (DM) is crucially important; however, the atherogenic dyslipidaemia (including low high-density lipoprotein cholesterol and hypertriglyceridaemia) typically encountered in type 2 DM is often managed inadequately. Evidence from the Fenofibrate Intervention and Event Lowering in Diabetes study suggests that fenofibrate reduces the risk of long-term macrovascular and microvascular type 2 diabetic complications, especially in patients demonstrating features of the metabolic syndrome. Fenofibrate represents a useful treatment option for controlling cardiovascular risk in type 2 diabetes patients in the community setting.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Type II Diabetes I: Introduction
Diabetes Mellitus: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis